A meta-analysis of four double-blind, randomized, controlled trials of the weight-loss drug Acomplia provides additional evidence that the drug has a propensity to cause anxiety and depression.
The research is reported in the November 17 issue of The Lancet.
"Taken together with the recent US Food and Drug Administration finding of an increased risk of suicide during treatment with rimonabant, we recommend increased alertness by physicians to these potentially severe psychiatric adverse reactions," the researchers state.
Patients taking rimonabant had a 40% higher risk of serious adverse events, Dr. Astrup and colleagues found.
PS - you think I'm joking about the pallbearers.............?
No comments:
Post a Comment